1092443-55-4

Basic information

• Product Name: BS194
• Synonyms: BS194;(2S,3S)-3-(7-(benzylaMino)-3-isopropylpyrazolo[1,5-a]pyriMidin-5-ylaMino)butane-1,2,4-triol;1,2,4-Butanetriol, 3-[[3-(1-Methylethyl)-7-[(phenylMethyl)aMino]pyrazolo[1,5-a]pyriMidin-5-yl]aMino]-, (2S,3S)-;(2S,3S)-3-[[3-(1-Methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-1,2,4-butanetriol
• CAS NO: 1092443-55-4
• Molecular Formula: C₂₀H₂₇N₅O₃
• Molecular Weight: 385.46008
• Mol File: 1092443-55-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BS194(CAS DataBase Reference)
• NIST Chemistry Reference: BS194(1092443-55-4)
• EPA Substance Registry System: BS194(1092443-55-4)

Safety Data

• Hazardous Substances Data: 1092443-55-4(Hazardous Substances Data)

Usage

Uses

Used in Food and Beverage Industry:
BS194 is used as a food preservative and antimicrobial agent for extending the shelf life of food products. It is particularly effective in acidic foods and beverages, such as sodas, fruit juices, and pickles, due to the properties of its main active ingredient, sodium benzoate.
BS194 is used as a safety measure to prevent spoilage and contamination in the food and beverage industry, ensuring the quality and safety of products for consumers. Its antimicrobial properties help maintain the freshness and taste of food products, while its preservative action reduces the risk of foodborne illnesses caused by bacterial growth.
However, it is important to note that the long-term consumption of sodium benzoate and its potential to form benzene when combined with certain ingredients have raised concerns about its safety. As a result, the usage and safety regulations of BS194 are subject to ongoing discussions and evaluations to ensure the well-being of consumers and the sustainability of the food and beverage industry.

Upstream product

• 1092444-51-3 tert-butyl benzyl(5-(((2S,3S)-1-((tert-butyldimethylsilyl)oxy)-3,4-dihydroxybutan-2-yl)amino)-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 771510-32-8 5,7-dichloro-3-iso-propyl-pyrazolo[1,5-a]pyrimidine 
• 1092444-50-2 (R)-tert-butyl benzyl(5-((1-((tert-butyldimethylsilyl)oxy)but-3-en-2-yl)amino)-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 625-28-5 Isovaleronitrile 
• 771510-25-9 3-isopropylpyrazolo[1,5-a]pyrimidine-5,7-diol 
• 1092444-33-1 benzyl (5-chloro-3-isopropylpyrazolo[1,5-a]pyrimidin-7-yl)carbamic acid tert-butyl ester 
• 1092443-98-5 benzyl-(5-chloro-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)-amine 
• 151521-49-2 4-isopropyl-1 H-pyrazol-5-amine 
• 771510-15-7 2-formyl-3-methylbutanenitrile 

Relevant articles and documents

A novel pyrazolo[1,5- a ]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration

Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression. Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs. Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compound, 4k (BS-194), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, respectively). Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases. Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI50 = 280 nmol/L). Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice. When administered at a concentration of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation. These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.

SELECTIVE INHIBITORS FOR CYCLIN-DEPENDENT KINASES

This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.